The results imply that APE/AFE administration inhibited CAC by inactivating PI3K/Akt/mTOR signal transduction and its downstream target PPAR-γ, which might be a latent agent for the blocking of CRC genesis and progenesis. This evidence concerns the gene AKT1 and colorectal carcinoma.